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Photodynamic therapy (PDT) for the treatment of cancerous and
non-cancerous lesions is becoming an accepted therapy. The
process involves the presence of a photoactive agent which is acti-
vated in the target tissue by non-thermal light resulting in necrosis.
Porfimer sodium (Photofrin, Quadra Logic Technologies) is the
only commercially available sensitizer in the USA. Prolonged skin
photosensitivity lasting as long as 3 months in some cases and
activation at 630 nm which limits the depth of light penetration in
tissue has resulted in the search for other photosensitizing
compounds. One such agent that is now in phase I/II trials is
pyropheophorbide-alpha-hexyl-ether (HPPH, Photochlor). HPPH
is derived from pheophorbide-a obtained from Spirrulina algae.
Potential advantages of HPPH over porfimer sodium are a major
visible absorption peak at 665 nm allowing slightly increased
tissue penetration and rapid clearance from normal skin in the
murine model (Bellnier et al, 1993). If the rapid skin clearance
occurs in other species, decreased skin photosensitivity might be
the result. Previous work in dogs indicated a mean serum half-life
is 26 h and no toxicity at an intravenous (i.v.) dose of 0.3 mg kg–1
(Payne et al, 1996).
Tumours located where light can be easily applied such as the
oral cavity are good candidates for PDT therapy. The ideal
tumours to treat with PDT would be those that do not metastasize
since no systemic anti-tumour effects are present with PDT. Dogs
with gingival squamous cell carcinomas (SCC) are good candi-
dates for PDT. Oral SCCs are locally aggressive with local bone
invasion seen in 77% of cases. Only 10% of tumours spread to
regional lymph nodes and 3% metastasize to the lungs (Head,
1990). Aggressive surgical therapy is the present recommended
treatment for these tumours and can result in long remissions.
Removal of large portions of the mandible can be cosmetically and
aesthetically displeasing. This study was undertaken to treat




Eleven client-owned dogs presented to the University of Missouri
Veterinary Medical Teaching Hospital for treatment of oral SCC
were used (Table 1). The clients were informed that aggressive
surgery was the current accepted treatment for oral SCCs. The
dogs were entered into the experimental study at the request of the
owners. The ages ranged from 7 to 13 years. Nine dogs were
females and two were males. The tumours had been detected 1–5
months prior to presentation and the tumours of four dogs had
been locally excised during that period but had recurred. Physical,
radiographic and laboratory examination indicated that neither
spread of the tumour from the local area nor organ failure would
limit the dog’s life. All tumours were histopathologically
confirmed to be SCCs.
Tumour staging
The tumours were staged as: T0 – no evidence of tumour; T1 –
tumour < 2 cm maximum diameter; T2 – tumour 2–4 cm
maximum diameter; T3 – tumour > 4 cm maximum diameter. All
tumours were substaged as: a – without bone invasion; b – with
bone invasion. Tumour staging for the 11 dogs is given in Table 1.
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This study was performed under an investigational new animal
drug (INAD) permit obtained from the United States Food and
Drug Administration. The photosensitizer (Photochlor-HPPH)
was kindly provided by Dr Thomas J Dougherty (Roswell Park
Cancer Institute, Buffalo, NY, USA) in an aqueous solution (0.1%
polysorbate 80, 2.0% ethanol, 5.0% dextrose in water). The dose
was 0.3 mg kg–1 which was injected i.v. 48 h prior to surgical
debulking and irradiation.
An argon ion pumped dye laser (Coherent Laser Systems
Innova 200 and 599 respectively, San Jose, CA, USA) tuned to
665 nm wavelength was used for the treatments. A quartz optic
fibre with a sapphire microlens affixed at the distal end was used
to ensure uniform light delivery at the surface of the patient (PDT
Systems Inc., Santa Barbara, CA, USA) The laser and fibre output
were monitored before and after each treated area with a power
meter (Coherent, model 30 W).
Anaesthesia and analgesia
All treatments were accomplished under general anaesthesia. The
dogs were administered atropine, xylazine and morphine as pre-
anaesthetic agents. Anaesthesia was induced with thiopental and
maintained after tracheal intubation with isoflorane. Morphine
was administered after anaesthetic recovery and for 18 h post-
treatment.
Treatment
Tumours that were thicker than 1 cm, as determined by measuring
the tumour or extent of the tumour on radiographs, were surgically
debulked just prior to irradiation to reduce the thickness to less
than 1 cm with no intent to completely remove the neoplastic
tissue. Tissue was obtained from the surgical bed and examined for
tumour cells. Surgical debulking was performed in eight dogs,
while three had tumours small enough that surgery was not neces-
sary (Table 1). Of the eight dogs that had surgery, six dogs had
histopathologic evidence of residual tumour. The specimens were
too small in the other two for an interpretation. Any teeth that were
loose were removed.
The tumours or surgical beds were irradiated with 665 nm
wavelength light, a calculated incident light dose of 100 J cm–2,
and a fluence rate of 100 mW cm–2. Each treated area was a circle
described by the light spot from the optic fibre. The sapphire lens
on the distal end of the fibre provided uniform power density
within the illuminated spot. The tumour bed and approximately
3 mm of normal appearing tissue were then irradiated. A 3 cm spot
was the largest that was used. The duration of the treatment for
each treated area was 16 min, 40 s. Most tumours required more
than one spot. In this case the spots were overlapped to avoid
untreated areas. Tissue outside of the treatment field was shielded
from incident laser light using moistened gauze and paper surgical
drapes. The fibre was positioned so that light could be delivered
nearly perpendicular to the tissue. Several spots were necessary for
some dogs as a result of the contour of the tissue.
Varying degrees of swelling were observed after irradiation.
This swelling resolved within 4 days. All dogs ate when offered
food the day after treatment. Dogs were released to owners for
follow-up care as early as 1 day post-treatment. The owners were
instructed to avoid exposing the dogs to direct sunlight either
indoors or outdoors for more than 15 min three times daily. The
light restriction was to last for 4 weeks. No owners observed
photophobia. No dog experienced a general reaction such as
redness or swelling as has been described in humans. An area on
the dorsal portion of the nose of one dog became ulcerated
between 1 and 2 weeks post-treatment. The dog was housed
outside after treatment. The lesion was healed by post-treatment
week 4. Darkening of the skin on the ventral abdomen occurred in
another dog.
RESULTS (Table 1)
Normal teeth that were included in the treatment field became
loose within 4 weeks of therapy. Most lesions healed within
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Table 1 Animal information and outcome
Gender Age Tumour Time present Previous Tumour size* Surgical Tumour Tumour Outcome/ 
(years) location before PDT treatment (cm) debulking remaining stage time to
(months) outcome
(months)
Female (spayed) 9 Rostral left mandible 1.5 None 2.4 ´ 1.6 Yes Yes T2b Died – no tumour
recurrence (29)
Female (spayed) 7 Caudal right maxilla 5.0 Surgical removal 2.2 ´ 1.6 No Yes T2a Died – no tumour
recurrence (36)
Male 10 Middle right mandible 2.5 None 6.8 ´ 5.4 Yes Yes T3b Tumour
recurred (9)
Female 10 Rostral left mandible 1.5 None 2.1 ´ 1.9 Yes No T2a Alive (49)
Female (spayed) 8 Rostral left mandible 1.0 Surgical removal 0.9 ´ 0.7 Yes No T1a Alive (36)
Male (castrated) 10 Rostral left mandible 2 None 2.3 ´ 1.8 Yes Yes T2b Died – no tumour
recurrence (23)
Female (spayed) 7 Rostral left maxilla 1 Surgical removal 1.1 ´ 1.0 No Yes T1b Alive (30)
Female (spayed) 11 Caudal left mandible 3 Surgical removal 2.5 ´ 1.2 No Yes T2a Died – no tumour
recurrence (17)
Female (spayed) 10 Rostral right mandible 2 None 2.5 ´ 1.8 Yes Yes T2b Tumour remained –
euthanatized (6)
Female (spayed) 13 Rostral bilateral maxilla 1 None 2.7 ´ 2.5 Yes Yes T2b Alive (23)
Female (spayed) 13 Rostral left mandible 1 None 2.4 ´ 2.1 Yes Yes T2b Tumour metastasis (3)
*Caliper measurement of grossly estimated tumour margin: longest length ´ longest width perpendicular to length.6 weeks but three dogs required either removal of a bone
sequestrum or surgical debridement of devitalized bone to aid
healing. One dog had no apparent benefit from PDT with recur-
rence or residual tumour present at 1 month after treatment.
Metastatic disease in the regional lymph node was present in one
dog 3 months after treatment, however there was no return of
tumour in the treated area. One dog had confirmed recurrence and
was euthanatized at 9 months after treatment. Four dogs died of
unrelated causes and had no evidence of the oral SCC at 17, 23, 29
and 36 months after treatment. Four dogs were alive with no
evidence of tumour recurrence at the time of writing 23, 30, 36 and
49 months after treatment. Median survival of the 11 treated dogs
was 29 months.
DISCUSSION
Gingival SCC is the second most common malignant neoplasm of
the canine oral cavity. The tumours are aggressive with local bone
invasion seen in 77% of cases. Loss of teeth due to bone destruc-
tion is common. Only 10% of tumours spread to regional lymph
nodes and 3% metastasize to the lungs (Head, 1990). Local exci-
sion of the tumours is of little benefit with a median survival of
9 months and about 35% of dogs tumour-free at 1 year (Todoroff
and Brodey, 1979). Aggressive surgery in the form of total or
partial mandible resection results in a median survival of 15.8
months (Salisbury and Lantz, 1988). Radiation therapy will result
in complete remission in 16% of tumours for 1 year. The current
recommended therapy is resection of the mandible or maxilla to
assure tumour-free surgical borders. Post-operative complications
include prehension dysfunction, excessive drooling or salivation,
and palatal ulceration secondary to malocclusion. For those
tumours that cannot be surgically removed, radiation therapy is the
treatment of choice. Radiation therapy results in mucositis. PDT is
without the complications of surgery and radiation therapy and,
because oral SCC do not readily metastasize, local therapy is
potentially curable.
Previous work with PDT in SCCs suggests that it would be
benefical in treatment of canine oral SCCs. A human pharyngeal
SCC cell line has been shown to be one of the most sensitive cell
types to PDT in vitro (Boonkitticharoen et al, 1997). Early-stage
disease SCC of the head and neck treated with Photofrin resulted
in 20 of 26 (77%) people achieving a complete response based on
physical examination and histopathological confirmation. Sixteen
people remained free of tumour for periods up to 51 months
(Wenig et al, 1990). Using Photofrin in dogs for oral SCCs, the
median remission was 13 months, with 11 of 14 dogs still alive at
the time of writing (Beck, 1992).
The only other report on the usage of HPPH for naturally occur-
ring tumours was treatment of SCC on the face in cats. It was
found to be effective for early-stage disease (Magne et al, 1997).
The results using other sensitizing agents for facial SCC in cats
were similar (Peaston et al, 1993; Chang et al, 1998).
Our results were excellent for T1 and T2 disease and were
comparable to surgery and better than radiation therapy. The
cosmetic results were superior. Healing complications were
minimal, however some lesions required up to 6 weeks to resolve.
This delayed healing has been reported in a rabbit model where
wounds created by PDT were slower to heal than those surgically
produced (Meyer et al, 1991). Healing was delayed because of
bone sequestrum in two dogs and bone necrosis in the other dog.
Upon removal of the sequestrum and necrotic bone healing
occurred. PDT has been touted as sparing normal tissue but the
validity of the concept has been questioned (Grant et al, 1997).
Applying PDT to the mandibles of normal rabbits produced no
bone effects (Meyer et al, 1991). A possibility in our cases is that
by destroying the tumour that was invading bone the blood supply
was also destroyed. However, one of the dogs with a bone
sequestrum did not have evidence of bone invasion. The peridontal
ligament or its blood supply was another structure that was
damaged by PDT. Normal teeth that were included in the treatment
field became loose and were easily removed. Irradiation of normal
teeth has been reported to have no effect (Meyer et al, 1991).
Two of the dogs that failed to have a sustained remission had
large tumours. One of the dogs appeared to have remission with
superficial healing occurring. The most likely explanation for
failure in these cases is the failure to achieve light penetration to
the complete tumour depth (Grant et al, 1997). The more aggres-
sive nature of the larger tumours could also be responsible for
failure of sustained remission because larger tumours also fail after
surgical removal (Salisbury and Lantz, 1988). The third dog that
failed treatment did so because of metastasis. Local control of the
tumour appeared to be achieved. Metastasis in this case would
likely have occurred with surgery or radiation therapy also.
PDT using HPPH as the photosensitizing agent was successful
in the treatment of canine oral SCC that were smaller than 4 cm in
diameter. The invasion of bone by the tumour did not affect the
outcome. These results are similar to those obtained using
Photofrin. Although the results may not be directly applicable to
humans, previous work with PDT in dogs indicates that tumour
response is similar to response in humans (Beck, 1992). Surgical
debulking followed by PDT should be considered as a possible
primary treatment in human oral SCC.
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